marnetegragene autotemcel
| Brand name | kresladi |
|---|---|
| Active ingredient | marnetegragene autotemcel |
| Strength | 0.34 to 6.1 × 10^6 cells/mL (including 0.32 to 6.1 × 10^6 CD34+ cells/mL) |
| Dosage form | Suspension |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | March 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.